At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
In Brief
A Phase 2 clinical trial evaluating Dasatinib and Letrozole for Metastatic Breast Cancer. Completed, enrolled 120 participants across 27 sites.
Detailed Summary
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
CollaboratorsUS Oncology Research
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartAug 2008
Primary CompletionJun 2014
TodayJul 2026
First PostedJun 12, 2008
Enrollment StartAug 1, 2008
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 18.1 years ago
Interventions
Dasatinibdrug
Tablets, Oral, 100 mg once daily, up to 2 years
Letrozoledrug
Tablets, Oral, 2.5 mg, once daily, up to 2 years